Related Experiment Video

Updated: Apr 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions

Sumanta K Pal1, Adriana Hu1, Mark Chang1

  • 1City of Hope Comprehensive Cancer Center, Duarte, California.

Clinical Advances in Hematology & Oncology : H&O
|June 4, 2014
PubMed

Insights

New immune therapies targeting programmed death-1 (PD-1) and its ligand (PD-L1) show promise for treating metastatic renal cell carcinoma (mRCC). These agents may offer a novel approach in the evolving treatment landscape for mRCC.

Area of Science:

  • Oncology
  • Immunotherapy
  • Renal Cell Carcinoma Research

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has shifted from solely immune-based strategies to include targeted therapies.
  • Recent advancements show a resurgence in immune-based approaches, including vaccines and immunomodulatory agents.

Purpose of the Study:

  • To review the clinical development of agents targeting the programmed death-1 (PD-1) receptor and its ligand (PD-L1).
  • To discuss the potential role of PD-1/PD-L1 inhibition within the current treatment paradigm for mRCC.

Main Methods:

  • Review of clinical trials and literature on PD-1/PD-L1 inhibitors in mRCC.
  • Analysis of the mechanism of action for PD-1/PD-L1 blockade in the tumor microenvironment.

Main Results:

  • Monoclonal antibodies targeting PD-1 (e.g., nivolumab, lambrolizumab) and PD-L1 (e.g., MPDL3280A) are in various clinical development stages.
  • The PD-1/PD-L1 pathway is crucial in immune evasion by tumors, leading to T-cell anergy.

Conclusions:

  • PD-1/PD-L1 inhibitors represent a significant advancement in immuno-oncology for mRCC.
  • Further research is needed to define the optimal placement of these novel immunotherapies in the mRCC treatment algorithm.

More Related Videos

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

22.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K